Our Strategy

Strategy

Our strategy is to maximize the value of our existing pipeline by advancing our lead clinical-stage asset efficiently and with disciplined focus, rather than expanding into new discovery programs.

We are prioritizing execution over expansion, focusing our resources on:

Advancing our lead program through clinical development
Generating pivotal data at defined inflection points to validate our approach; and
Creating multiple opportunities for strategic partnering and/or licensing.

Approach

This approach enables us to concentrate our resources on our lead programs and accelerate pathways to value creation.

Our goal is to leverage our drug discovery, clinical development and project management expertise to develop distinctive novel small molecule therapeutics to treat the complex biology of metabolic, inflammatory and fibrotic diseases to address a wide range of significant unmet needs via partnering opportunities. We do this through our wholly-owned subsidiary Caledon Bioscience.